Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoblastic Leukemia, Acute, Childhood
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Trial Timeline
Jul 3, 2015 → Sep 4, 2020
NCT ID
NCT01614197About Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine
Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine is a phase 1 stage product being developed by Pfizer for Lymphoblastic Leukemia, Acute, Childhood. The current trial status is completed. This product is registered under clinical trial identifier NCT01614197. Target conditions include Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma.
What happened to similar drugs?
2 of 13 similar drugs in Lymphoblastic Leukemia, Acute, Childhood were approved
Approved (2) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01614197 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoblastic Leukemia, Acute, Childhood